How does the USPTO use the computer readable form (CRF) of the “Sequence Listing”?

The USPTO uses the computer readable form (CRF) of the “Sequence Listing” for several important purposes, as outlined in the MPEP: The information on the computer readable form will be entered into the Office’s database for searching and printing nucleotide and amino acid sequences. This electronic database will also enable the Office to provide published…

Read More

Does the USPTO return or preserve the computer readable form (CRF) submitted on read-only optical discs?

No, the USPTO does not permanently preserve or return computer readable forms (CRFs) submitted on read-only optical discs. The MPEP clearly states: The Office does not desire to be bound by a requirement to permanently preserve computer readable forms submitted on read-only optical disc(s) for support, priority or correction purposes. Thus, once use of the…

Read More

How does the USPTO handle confidentiality of sequence data in pending applications?

The USPTO maintains strict confidentiality of sequence data in pending applications, in compliance with 35 U.S.C. 122. The MPEP clarifies: It should be noted that the Office’s database complies with the confidentiality requirement imposed by 35 U.S.C. 122. Unpublished pending application sequences are maintained in the database separately from published or patented sequences. That is,…

Read More

What is the requirement for submitting a computer readable copy of the “Sequence Listing”?

According to 37 CFR 1.821(e), a computer readable form (CRF) of the “Sequence Listing” must be submitted in applications filed under 35 U.S.C. 111(a) or in national stage applications submitted under 35 U.S.C. 371. The MPEP states: A separate computer readable form must be submitted via the USPTO patent electronic filing system or on read-only…

Read More